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Introduction
Heavy alcohol use is estimated to result in 5.3% of all deaths worldwide. Moreover, this percentage is higher in younger groups, e.g. 13 .5% of deaths between 20 and 39 years of age are attributable to alcohol (1) . This high toll has spurred an ongoing global research effort to develop and optimize suitable therapies to treat alcohol use disorders (AUD). Currently, the FDA has approved 3 pharmacotherapies for the treatment of AUD; disulfiram, acamprosate, and naltrexone. Naltrexone, a non-selective opioid receptor antagonist, has been approved since 1994, but a low rate of naltrexone prescriptions has been reported (2) . An analysis of prescribing behavior showed that addiction medicine physicians prescribed naltrexone to only 13% of their AUD patients, and that prescription frequency was associated with the physician's perception of naltrexone efficacy. Although numerous clinical trials have shown significant effects of naltrexone on primary and secondary drinking outcomes, the effect size is modest (3) . For example, a recent meta-analysis of 27 randomized clinical trials including 2253 patients found that naltrexone decreased the chance of relapse to heavy drinking by only 15% compared to placebo (4, 5) .
In an attempt to explore possible ways to increase the effect size, potential moderators of the response to naltrexone have been a sought (6, 7) .
The efficacy of naltrexone has long been attributed to its interactions with the mu opioid receptor, despite its non-selectivity between all three opioid receptor subtypes (mu, delta, and kappa) (8) . This perspective is largely driven by the affinity profile of naltrexone, with higher affinity for mu (K i = 1.0 nM) compared to delta and kappa (K i =149 nM and 3.9 nM, respectively) (9) . Further, polymorphisms of the mu opioid receptor gene, OPRM1, have been observed to modify naltrexone efficacy (10-12); although not in all studies (13, 14) . Meanwhile, recent evidence has also implicated the delta and kappa opioid receptors and their endogenous ligands in AUD (15, 16 ). For example, neuroimaging studies using positron emission tomography (PET) imaging with the selective kappa opioid receptor (KOR) radioligand (17) . In addition, the endogenous ligands of all three receptors have been reported to be released in rats upon acute alcohol administration (18) (19) (20) . Consistent with their role in AUD, it has been suggested that therapeutic approaches targeting the KOR have the potential to achieve greater efficacy in reducing drinking than non-selective antagonists like naltrexone (21) . This implies that the mechanism through which naltrexone exerts its effect extends beyond mu-pharmacology and emphasizes the potential influence of the KOR on successful naltrexone treatment outcome.
Further understanding of the factors involved in moderating naltrexone treatment outcomes could lead to greater overall therapeutic efficacy, through identification of either susceptible patient groups or specific pharmacological targets. We hypothesized that KOR availability was related to behaviour during an alcohol drinking paradigm (ADP) and the effect of naltrexone hereon. 
Methods & Materials
Subjects
We recruited non-treatment seeking participants who met DSM-IV criteria for alcohol dependence and were drinking at or above 20 drinks/week for women and 25 drinks/week for men as determined with a 90-day Timeline Followback (TLFB) assessment (24) . Written informed consent was obtained for each Subjects participated in two PET scans and alcohol drinking paradigm (ADP) sessions. The first PET scan and ADP session (APD1) were conducted prior to initiation of naltrexone treatment. The second PET scan and ADP session (ADP2) were conducted after 7-8 days of naltrexone treatment. The second PET scan, conducted two hours after the last naltrexone dose, was used to measure occupancy. Results will be reported in a separate publication. ADPs were performed on average 2.2 ± 0.5 days after the corresponding PET scan and never on the same day. A progressive dosing regimen was used to minimize the chance of adverse effects. According to this regimen, participants received 25 mg naltrexone on the first day, 50 mg on the second, and 100 mg for the remaining days up to and including the day of ADP2.
Immediately prior to PET procedures and the ADPs urine toxicology screens and breath alcohol tests were conducted to verify overnight abstinence from alcohol and other substance use. All women of child-bearing age received urine pregnancy tests to confirm that they were not pregnant prior to either procedure.
PET procedures
Dynamic PET scans were acquired on a High Resolution Research Tomograph (HRRT) scanner (Siemens/CTI, Knoxville, TN, USA) for 90 min starting with [ 11 C]-LY2795050 bolus injection over 1 min.
Arterial lines were placed in the arms of the participants to obtain blood samples for measurement of
]-LY2795050 concentrations in plasma. After reconstruction and motion correction, partial volume correction was performed as described earlier (27) . A structural T1 image was acquired on a 3T scanner (Trio, Siemens Medical Systems, Erlangen Germany) for anatomical registration of the PET data.
Individual images were registered to MNI space and six bilateral regions of interest were identified; amygdala, pallidum, striatum, hippocampus, frontal cortex, and cingulate cortex. For every region, a time-activity curve was extracted and modeled using the multilinear analysis 1 (MA1) method (t* = 30 min) to estimate the total volume of distribution (V T ) (28) , where V T is equal to the sum of non-specific and specific binding. Since we have previously shown that exposure to alcohol does not change nonspecific binding, we use V T as a surrogate measure of kappa receptor availability (17) . In addition, a voxel-wise analysis was conducted using the same model. Because of noise in the dynamic PET data at the voxel level, the MA1 model occasionally produced poor fits and non-physiological V T values at individual voxels. Therefore, voxels with a V T below 0 or above the 95 th percentile were replaced with the median of their 26 nearest-neighbor voxels. Voxel-wise regression was performed in SPM12 using variables of interest as covariates (29) . For the craving measures, the area under the curve was used as a summary statistic in these voxel-wise regressions. Thresholds in SPM were set at p < 0.005 uncorrected at the voxel level and cluster-extent > 150.
ADP Procedures
Subjects were admitted to the Hospital Research Unit (HRU) at Yale-New Haven Hospital on the day of each ADP. At 4 pm, participants began the alcohol drinking session using procedures based on our earlier work (22, 23, 30) . Briefly, following completion of baseline measures of craving and other subjective reports, participants consumed a priming alcoholic drink (0.03 g/dl) followed by a 50 min monitoring period, and were then exposed to three 1-hour self-administration periods. During each of the three self-administration periods, participants were offered a choice between consuming up to 4 alcoholic drinks (0.015 g/dl) or receiving $3/drink declined; drinking during the ADP was quantified as the total number of drinks consumed from the 12 drinks offered during the three self-administration periods. Subjects could only participate in the study if they liked and regularly drank mixed drinks. Based on their own reports, the drinks presented during the ADP were each participant's favorite combination
of juice and ethanol. Drinks were mixed to contain 10% v/v ethanol, which is similar to commercial mixed-drink cocktails.
In addition, craving was assessed throughout the laboratory session with both the Yale Craving Scale (YCS) and Alcohol Urge Questionnaire (AUQ) questionnaires (31, 32) ( Figure 1 ). After completion of the ADP session, participants spent the night at the Hospital Research Unit (HRU) for monitoring and were discharged the next morning. Subsequently, participants received once daily oral generic naltrexone for six days as outpatients; participants came in daily (between 10 am -12 pm) to take their naltrexone dose and report any adverse events. On the 7 th or 8 th day (depending on scheduling at the HRU) they completed the ADP procedure again, following administration of a last dose of naltrexone at 10 am.
Upon discharge, participants received an intervention that included feedback about their heavy-drinking behavior from a licensed clinical psychologist (33) . ADP outcomes were the total number of drinks consumed during the self-administration periods in each session and craving assessed using the YCS and AUQ (obtained at 17 timepoints).
Analysis
Data analyses were conducted using JMP pro 13 (SAS Institute, Cary, USA). Two primary outcomes were investigated: the difference in the total number of drinks consumed from the first to the second ADP, and the craving experienced during each ADP. LASSO regressions evaluated the associations between the difference in drinking and baseline KOR availability, whereas the longitudinal craving data (AUQ and YCS) were modelled with linear mixed models. Mixed models included experimental period and ADP number and their interaction as fixed effects, and subjects as a random effect. Variance-covariance structure of repeated measures per ADP were modeled using a first-order auto-regressive structure.
Multiple testing correction was performed using the Benjamini-Hochberg procedure (34) . Demographics
and descriptive statistics were reported as median (range). Statistical outcomes were reported with their standard error and significance was defined at the 0.05 significance level.
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Results
Baseline characteristics
Participants ( highly correlated (r = 0.93, p < 0.0001) and age has previously been shown to have no effect on KOR availability, only years of drinking was included in the analysis as a covariate (17) .
Alcohol drinking paradigm
Participants consumed significantly fewer drinks during the self-administration period in the second ADP 
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Kappa Receptors and Drinking
An analysis including all regions showed that a greater reduction in drinking was observed in subjects with a lower KOR availability (effect: -2.9 ± 1.3 (i.e. average reduction in drinking per one increase in 
Kappa receptors and craving
Analysis over all regions showed a significant association between KOR availability at baseline and craving as assessed with YCS (F (3,9808) = 12.6, p < 0.0001). Post-hoc analysis showed that higher kappa availability was associated with higher time-varying craving during both ADPs in all regions, i. Voxel-wise analyses covarying for YCS and AUQ did not find any clusters of significant association between kappa availability and craving.
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Discussion
Reduction in drinking and craving following 100 mg/day of naltrexone in non-treatment seeking heavy drinkers were associated with KOR availability prior to naltrexone treatment. Specifically, higher KOR availability in the striatum, insula, cingulate and prefrontal cortex were each associated with smaller reduction in the number of consumed drinks during the ADP before and after naltrexone treatment.
Higher KOR availability in both limbic and frontal regions was found to be associated with higher craving during the ADPs, as measured with the AUQ and YCS.
The current results agree with our previous findings that naltrexone decreases the amount of alcohol consumed and the urge to drink in individuals with AUD given a choice between alcohol and money (22) .
The exact molecular mechanism through which naltrexone exerts these effects is not clear, potentially because of the complex pathway through which alcohol exerts its rewarding effects: alcohol-induced dopamine release depends on dopamine, serotonin, glutamate, glycine, cannabinoid, and opioid receptors, and is also the result of a direct excitatory effect (35) (36) (37) (38) (39) (40) (41) (42) . However, it has been established, preclinically, that naltrexone can attenuate ethanol-induced dopamine release in brain regions associated with reward, such as the nucleus accumbens (43) . This attenuation is thought to be a result of the regulatory opioidergic system, which may modify dopamine release through the opposing effects of the mu and kappa opioid systems. It has been shown that mu receptor agonist binding in the ventral tegmentum area, the origin of mesolimbic dopaminergic projections, increases tonic dopamine levels, whereas KOR agonists decrease basal dopamine (44) (45) (46) (47) (48) . KOR activity induces a decrease in mood, whereas KOR antagonism can block drug withdrawal effects (49, 50). Recent studies have suggested that the underlying KOR-mediated hyperpolarization of dopaminergic neurons could vary according to the target region of those neurons (51, 52) . KOR-mediated inhibition is thought be caused by a direct effect on dopaminergic terminals, but KOR activation can disinhibit dopaminergic activity (50, 53) . This excitatory effect is based on the inhibition of somatodendritic dopamine release that would otherwise M A N U S C R I P T
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have had an inhibitory effect via the D2 dopamine receptor on the dopaminergic neurons (53).
Interestingly, D2 dopamine receptor down-regulation has been proposed as a mechanism for the enhanced dopamine release after repeated, but not acute KOR agonist exposure observed in animals (48) . Repeated KOR agonist exposure did however, not decrease the number of available KOR (54) .
Finally, the respective timing of KOR agonists and dopamine release-inducing drugs are probably important (55) .
If kappa opioid receptors decrease tonic dopamine levels, individuals with higher kappa receptor activity could have lower basal dopamine levels. It has been shown that a hypoactive dopaminergic system is linked with higher craving and alcohol consumption (56) , which is consistent with our results. Nonselective opioid antagonists can decrease basal dopamine levels through their antagonistic effect on the mu receptor (57) . Therefore, we would expect that individuals in a hypodopaminergic state would benefit less from non-selective opioid antagonist treatment. This explanation remains speculative as the dynamic between chronic KOR activation and dopamine levels, described above, is complex and not yet fully understood. We observed that participants with higher KOR availability in the striatum, pallidum, cingulate and prefrontal cortex had a smaller reduction in the number of drinks consumed during the ADP after naltrexone treatment. No association with baseline craving or a trend towards a positive association between craving and naltrexone efficacy has also been reported (58, 59) . Therefore, future investigations are warranted to elucidate what aspects there are to the association between craving and naltrexone efficacy.
More severe AUD has been associated with weaker functional connectivity between the striatum and cognitive control areas, such as the insula, cingulate and prefrontal cortex (60) . In addition, addictive behavior has been reported to influence the kappa opioid system in brain regions involved in cognitive control (61) . This corroborates our results. We observed a relationship between the efficacy of naltrexone treatment and kappa receptor availability in the striatum, pallidum, insula, and cingulate and M A N U S C R I P T
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14 prefrontal cortex. An important overlap exists between these regions and the regions for which mu opioid receptor availability was found to be predictive of treatment outcome in cocaine abusers (62).
These observations provide further insight into the intricate balance between the pharmacological effects of mu and kappa (44) . Therefore, future studies investigating both mu and kappa opioid receptor availabilities in these regions in the same participants would be of interest.
Kappa opioid receptors may have a role in decreasing the hedonic state of an individual, thus increasing the tendency to restore their hedonic state through exogenous drugs (63, 64) . On the one hand this hypothesis is based on literature showing that polymorphisms in delta and kappa opioid receptors (OPRD1 and OPRK1, respectively) influence the effect naltrexone can have on the subjective experience of alcohol exposure (65) . In addition, OPRK1 polymorphisms have also been associated with higher cortisol levels, greater stress-induced craving, and greater relapse risk in cocaine addiction (66) . On the other hand this hypothesis is based on preclinical literature showing that KOR agonists reinstate drug and alcohol seeking behavior (67-70), whereas KOR antagonists attenuate the development of depressive-like behaviors in cocaine withdrawal (71) . Our finding that participants with higher KOR availability experienced a higher craving level during an ADP is consistent with the latter hypothesis and its underlying evidence. An additional finding is that KOR availability in the hippocampus was associated with the craving levels in each experimental phase during both ADPs. This region has been implicated before in an fMRI study which compared OPRK1 variant groups during stress cues (66) . Although more research is required, these previous results combined with our results suggest a potential link between the kappa opioid receptor, stress sensitivity, and craving.
Two major limitations of this study should be considered. First, low radiotracer binding may be related to low receptor availability or high endogenous ligand, or both. The competing endogenous ligand for (17) . In healthy controls, a strict balance exists between dynorphin concentrations and kappa receptor expression (61), but it is unclear whether alcohol abuse could shift this balance. Therefore, we cannot rule out the possibility that differences in dynorphin concentrations contributed to the observed effects.
Second, this study did not include a placebo group; as a result, it is possible that factors, other than naltrexone, contributed to the observed reduction in drinking and craving during ADP2. Although our study reports on an association between behavior and the KOR and not the efficacy of naltrexone, a placebo effect cannot be ruled out completely.
We showed a reduction in both drinking and craving during a controlled lab drinking session after a week of open label naltrexone. Moreover, the reduction in drinking was associated with KOR availability in frontal and limbic brain regions. KOR availability was also associated with craving during the ADPs. In summary, we believe we have established for the first time in vivo that the KOR has a role in both craving and the reduction in drinking after naltrexone. Future studies are necessary to understand the exact molecular mechanisms that underlie these observations. However, these results are an important advancement towards understanding the role of the KOR in motivational processes in AUDs. 
